abs324.txt	gene	expression	profiling	has	had	a	considerable	impact	on	our	understandingofbreastcancer	biology		duringthelast	decade	4	intrinsic	molecular	subtypes	ofbreast	cancer	(luminal	luminal	b	her2-enriched	[her2-e]	and	basal-like)	havebeen	identified	intensively	studied	in	this	article	we	review	discussthe	clinical	implications	of	the	2	non-luminal	(i	e	her2-e	andbasal-like)	within	hormone	receptor	(hr)-positive	disease	afterreviewing	32	studies	for	total	13	091	samples	∼8%	∼	15%	early	andmetastatic	hr+/her2-negative	breast	respectively	were	found	to	benon-luminal	clinically	hr+/her2-negative/non-luminal	have	beenassociated	with	estrogen	independence	chemo-sensitivity	resistance	cdk4/6inhibition	poor	outcome	interestingly	egfr/her2	tyrosine	kinase	inhibitionmight	be	value	hr+/her2-negative/her2-e	subtype	finally	her2-esubtype	hr+/her2	+	represents	30%	been	associated	withanti-her2	sensitivity	cdk4/6	inhibition	inthe	upcoming	years	retrospective	prospective	trials	evaluating	bothbiomarkers	should	lead	improvements	patient	outcomes
